1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Middle East & Africa Branded Generics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Middle East & Africa Branded Generics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Rising Adoption of Branded Generics owing to their Affordability to Favor Market
- 5.1.2 Spurring government initiatives for the development of branded generics augmenting the market growth
5.2 Market Opportunities
- 5.2.1 Loss of Patent Exclusivity of Branded drugs and Emergence of Biosimilars Brings Future Opportunities
5.3 Future Trends
- 5.3.1 Utilization of Branded Generics by Healthcare Providers and Professionals
5.4 Impact of Drivers and Restraints
6. Middle East & Africa Branded Generics Market Regional Analysis
6.1 Middle East & Africa Branded Generics Market Overview
6.2 Middle East & Africa Branded Generics Market Revenue 2020-2028 (US$ Billion)
6.3 Middle East & Africa Branded Generics Market Forecast Analysis
7. Middle East & Africa Branded Generics Market Analysis – by Therapeutic Application
7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Oncology: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.2 Cardiovascular Diseases
- 7.2.1 Overview
- 7.2.2 Cardiovascular Diseases: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.3 Diabetes
- 7.3.1 Overview
- 7.3.2 Diabetes: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.4 Neurology
- 7.4.1 Overview
- 7.4.2 Neurology: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.5 Gastrointestinal Diseases
- 7.5.1 Overview
- 7.5.2 Gastrointestinal Diseases: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.6 Dermatology Diseases
- 7.6.1 Overview
- 7.6.2 Dermatology Diseases: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.7 Analgesics & Anti-Inflammatory
- 7.7.1 Overview
- 7.7.2 Analgesics & Anti-Inflammatory: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
8. Middle East & Africa Branded Generics Market Analysis – by Distribution Channel
8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Retail Pharmacies: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Online Pharmacies: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Drug Stores
- 8.4.1 Overview
- 8.4.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9. Middle East & Africa Branded Generics Market Analysis – by Drug Class
9.1 Alkylating Agents
- 9.1.1 Overview
- 9.1.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.2 Antimetabolites
- 9.2.1 Overview
- 9.2.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.3 Hormones
- 9.3.1 Overview
- 9.3.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.4 Antihypertensive
- 9.4.1 Overview
- 9.4.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.5 Lipid-Lowering Drugs
- 9.5.1 Overview
- 9.5.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.6 Antidepressants
- 9.6.1 Overview
- 9.6.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.7 Antipsychotics
- 9.7.1 Overview
- 9.7.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.8 Antiepileptic
- 9.8.1 Overview
- 9.8.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
10. Middle East & Africa Branded Generics Market – Middle East and Africa Analysis
10.1 Middle East and Africa
- 10.1.1 Middle East & Africa Branded Generics Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 Middle East & Africa Branded Generics Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 South Africa:
Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.1.1 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.1.2 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.1.3 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
- 10.1.1.2 Saudi Arabia:
Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.2.1 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.2.2 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.2.3 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
- 10.1.1.3 UAE:
Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.3.1 UAE: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.3.2 UAE: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.3.3 UAE: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
- 10.1.1.4 Rest of Middle East and Africa:
Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.4.1 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.4.2 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.4.3 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Middle East & Africa Branded Generics Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Aspen Holdings
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 AstraZeneca
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bausch Health (Valeant Pharmaceuticals)
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Dr. Reddy's Laboratories Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GlaxoSmithKline plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Hetero
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Lupin
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Mylan N.V.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Par Pharmaceuticals
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Sandoz International Gmbh
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Sanofi
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 Teva Pharmaceutical Industries Ltd.
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For Middle East & Africa Branded Generics Market
